scispace - formally typeset
P

Peter S. Hammerman

Researcher at Novartis

Publications -  134
Citations -  32703

Peter S. Hammerman is an academic researcher from Novartis. The author has contributed to research in topics: Cancer & Lung cancer. The author has an hindex of 55, co-authored 133 publications receiving 26471 citations. Previous affiliations of Peter S. Hammerman include Samsung Medical Center & Harvard University.

Papers
More filters
Journal ArticleDOI

Mutational heterogeneity in cancer and the search for new cancer-associated genes

Michael S. Lawrence, +96 more
- 11 Jul 2013 - 
TL;DR: A fundamental problem with cancer genome studies is described: as the sample size increases, the list of putatively significant genes produced by current analytical methods burgeons into the hundreds and the list includes many implausible genes, suggesting extensive false-positive findings that overshadow true driver events.
Journal ArticleDOI

Comprehensive molecular profiling of lung adenocarcinoma: The cancer genome atlas research network

Eric A. Collisson, +318 more
- 01 Jan 2014 - 
TL;DR: In this paper, the authors report molecular profiling of 230 resected lung adnocarcinomas using messenger RNA, microRNA and DNA sequencing integrated with copy number, methylation and proteomic analyses.
Journal ArticleDOI

Comprehensive genomic characterization of squamous cell lung cancers

Peter S. Hammerman, +345 more
- 27 Sep 2012 - 
TL;DR: It is shown that the tumour type is characterized by complex genomic alterations, with a mean of 360 exonic mutations, 165 genomic rearrangements, and 323 segments of copy number alteration per tumour.
Journal ArticleDOI

Comprehensive genomic characterization of head and neck squamous cell carcinomas

Michael S. Lawrence, +309 more
- 29 Jan 2015 - 
TL;DR: It is shown that human-papillomavirus-associated tumours are dominated by helical domain mutations of the oncogene PIK3CA, novel alterations involving loss of TRAF3, and amplification of the cell cycle gene E2F1.
Journal ArticleDOI

Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing

TL;DR: Exome and genome sequences and whole-genome sequence analysis revealed frequent structural rearrangements, including in-frame exonic alterations within EGFR and SIK2 kinases, which are attractive targets for biological characterization and therapeutic targeting of lung adenocarcinoma.